IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Adnan M.M. Mjalli

Ser. No.

10/581,840

Filing Date

June 5, 2006

Title

Ligands for I7L as modulators of orthopox viruses and methods for

discovery thereof

Examiner

Michael L. Borin

Art Unit

1631

Atty. Docket:

TTP 2003-09-US

U.S.C. § 120.

Mail Stop: AMENDMENT Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. § 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08a.

It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

I. <u>COPIES</u>

1.	This application was filed <u>before</u> June 30, 2003. Accordingly, submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
2.	This application was filed <u>on or after</u> June 30, 2003. Accordingly, copies of cited U.S. patents and patent applications are not included Copies of foreign patent documents and non-patent literature are included.
3.	Under 37 C.F.R. § 1.98 (d) copies of the references listed on the attached PTO/SB08a forms are not required to be provided to the Patent and Trademark Office because they were previously submitted to or cited by the Patent and Trademark Office in an application relied upon for an earlier effective filing date under 35

11.	CONCISE EXPLANATION OF RELEVANCE						
		1.	DOCUMENTS IN THE ENGLISH LANGUAGE The patents, publications, or other information listed on the attached PTO/SB/08a are in the English language and do not require a statement of relevancy.				
		2.	DOCUMENTS NOT IN THE ENGLISH LANGUAGE				
			a. CONCISE EXPLANATION A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:				
			b. ENGLISH LANGUAGE SEARCH REPORT An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. MPEP 609.04(a)(III).				
			c. OTHER The following additional information is provided for the Examiner's consideration. English language abstract English language equivalent application				
III.	FEE:	<u>S</u>					
		1.	This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.				
		2.	This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of Final Rejection or Notice of Allowance.				
			a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).				

Serial No. 10/581,840 Information Disclosure Statement Page 3 of 4

		b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97 (e)(2).	
		c. Please debit Deposit Account No. 50-3216 in the amount of \$ in payment of the fee under 37 C.F.R. § 1.17(p). Two duplicate copies of this paper are attached.	
	3.	This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Please debit Deposit Account No. 50-3216 in the amount of \$	
4		a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more that three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).	
		b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97 (e)(2).	
PATE	NT TE	ERM ADJUSTMENT	
	Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this information disclosure statement. 37 C.F.R. § 1.704(d).		

IV.

Respectfully submitted,

Date: Oct. 19,2007

Samuel B. Rollins

Registration No. 52,180

TransTech Pharma, Inc. 4170 Mendenhall Oaks Pkwy Suite 110 High Point, NC 27265 Phone: (336) 841-0300